Jonathan Yingling
Chief Tech/Sci/R&D Officer chez ARCUS BIOSCIENCES, INC.
Profil
Jonathan Yingling is currently the Chief Scientific Officer at Arcus Biosciences, Inc. He previously held positions as Vice President-Oncology Discovery at Bristol Myers Squibb Co. from 2013 to 2015, and as Chief Scientific Officer & Senior Vice President at Idera Pharmaceuticals, Inc. from 2018 to 2020.
He also served as the Chief Scientific Officer at DNIB Unwind, Inc. Dr. Yingling completed his undergraduate degree at The College of William & Mary and obtained his doctorate from Duke University School of Medicine in 2016.
Postes actifs de Jonathan Yingling
| Sociétés | Poste | Début |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/01/2020 |
Anciens postes connus de Jonathan Yingling
| Sociétés | Poste | Fin |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Chief Tech/Sci/R&D Officer | 31/01/2020 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/10/2015 |
| DNIB UNWIND INC | Chief Tech/Sci/R&D Officer | - |
Formation de Jonathan Yingling
| The College of William & Mary | Undergraduate Degree |
| Duke University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
DNIB Unwind, Inc.
 DNIB Unwind, Inc. BiotechnologyHealth Technology DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA. | Health Technology |
